Symptoms of overdose include agitation, coma, convulsions, difficulty breathing, difficulty swallowing, dry mouth, extreme sleepiness, fever, intestinal blockage, irregular heart rate, low blood pressure, and restlessness.
A phenothiazine used as an antipsychotic agent and as an antiemetic.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Triflupromazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine. |
| Hydrocodone | Triflupromazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine. |
| Magnesium sulfate | The therapeutic efficacy of Triflupromazine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Triflupromazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine. |
| Mirtazapine | Triflupromazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine. |
| Orphenadrine | Triflupromazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Triflupromazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine. |
| Rotigotine | Triflupromazine may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Triflupromazine. |
| Sodium oxybate | Triflupromazine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Triflupromazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine. |
| Thalidomide | Triflupromazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Triflupromazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Aclidinium | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Aclidinium. |
| Mianserin | Mianserin may increase the anticholinergic activities of Triflupromazine. |
| Mirabegron | The risk or severity of urinary retention can be increased when Triflupromazine is combined with Mirabegron. |
| Potassium chloride | The risk or severity of gastrointestinal ulceration can be increased when Triflupromazine is combined with Potassium chloride. |
| Pramlintide | The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Triflupromazine. |
| Secretin porcine | The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Triflupromazine. |
| Tiotropium | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Tiotropium. |
| Topiramate | The risk or severity of hyperthermia and oligohydrosis can be increased when Triflupromazine is combined with Topiramate. |
| Umeclidinium | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Umeclidinium. |
| Amisulpride | Triflupromazine may increase the antipsychotic activities of Amisulpride. |
| Methylphenidate | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Methylphenidate. |
| Dexmethylphenidate | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Dexmethylphenidate. |
| Metoclopramide | The risk or severity of adverse effects can be increased when Metoclopramide is combined with Triflupromazine. |
| Quinagolide | The therapeutic efficacy of Quinagolide can be decreased when used in combination with Triflupromazine. |
| Sulpiride | Triflupromazine may increase the antipsychotic activities of Sulpiride. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Triflupromazine. |
| Lithium citrate | Lithium citrate may increase the neurotoxic activities of Triflupromazine. |
| Lithium hydroxide | Lithium hydroxide may increase the neurotoxic activities of Triflupromazine. |
| Mequitazine | Triflupromazine may increase the arrhythmogenic activities of Mequitazine. |
| Thiopental | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Thiopental. |
| Glycopyrronium | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Glycopyrronium. |
| Dipyridamole | The therapeutic efficacy of Triflupromazine can be decreased when used in combination with Dipyridamole. |
| Ephedrine | Triflupromazine may increase the neuromuscular blocking activities of Ephedrine. |
| Clevidipine | Triflupromazine may increase the neuromuscular blocking activities of Clevidipine. |
| Sar9, Met (O2)11-Substance P | Triflupromazine may increase the neuromuscular blocking activities of Sar9, Met (O2)11-Substance P. |
| Moxisylyte | Triflupromazine may increase the neuromuscular blocking activities of Moxisylyte. |
| Propacetamol | Triflupromazine may increase the neuromuscular blocking activities of Propacetamol. |
| Cocaine | Triflupromazine may increase the neuromuscular blocking activities of Cocaine. |
| Trimethaphan | Triflupromazine may increase the neuromuscular blocking activities of Trimethaphan. |
| Doxacurium | Triflupromazine may increase the neuromuscular blocking activities of Doxacurium. |
| Chloroprocaine | Triflupromazine may increase the neuromuscular blocking activities of Chloroprocaine. |
| Tubocurarine | Triflupromazine may increase the neuromuscular blocking activities of Tubocurarine. |
| Bambuterol | Triflupromazine may increase the neuromuscular blocking activities of Bambuterol. |
| Butyrylthiocholine | Triflupromazine may increase the neuromuscular blocking activities of Butyrylthiocholine. |
| Oxybuprocaine | Triflupromazine may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Benzonatate | Triflupromazine may increase the neuromuscular blocking activities of Benzonatate. |
| Dicoumarol | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Dicoumarol. |
| Phenindione | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Phenindione. |
| Warfarin | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Warfarin. |
| Phenprocoumon | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Phenprocoumon. |
| Acenocoumarol | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of adverse effects can be increased when Triflupromazine is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Coumarin. |
| (R)-warfarin | The risk or severity of adverse effects can be increased when Triflupromazine is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Ethyl biscoumacetate. |
| Fluindione | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Fluindione. |
| Clorindione | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Clorindione. |
| Diphenadione | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Diphenadione. |
| Tioclomarol | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Tioclomarol. |
| (S)-Warfarin | The risk or severity of adverse effects can be increased when Triflupromazine is combined with (S)-Warfarin. |
| Metyrosine | The risk or severity of extrapyramidal symptoms and CNS depression can be increased when Metyrosine is combined with Triflupromazine. |
| Succinylcholine | The metabolism of Succinylcholine can be decreased when combined with Triflupromazine. |
| Botulinum toxin type A | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Botulinum toxin type A. |
| Glucagon | Triflupromazine may increase the gastrointestinal motility reducing activities of Glucagon. |
| Botulinum toxin type B | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Botulinum toxin type B. |
| Eluxadoline | The risk or severity of constipation can be increased when Triflupromazine is combined with Eluxadoline. |
| Ramosetron | The risk or severity of constipation can be increased when Triflupromazine is combined with Ramosetron. |
| Ethanol | Triflupromazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Triflupromazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine. |
| Zimelidine | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Dapoxetine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Seproxetine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Escitalopram. |
| Milnacipran | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Desvenlafaxine. |
| Levomilnacipran | The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Triflupromazine. |
| Indalpine | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Alaproclate. |
| Esmolol | The serum concentration of Esmolol can be increased when it is combined with Triflupromazine. |